创新器械系列专题研究报告（一）：高血压迎来创新疗法，RDN开启微创降压新时代

Investment Rating - The report maintains a recommendation for the industry, indicating a positive outlook for investment opportunities in the renal denervation (RDN) sector [5]. Core Insights - The report highlights the significant burden of hypertension in China, with an estimated 245 million individuals affected, emphasizing the need for innovative treatment options beyond traditional medication [2][16]. - RDN is presented as a groundbreaking therapy for hypertension, demonstrating effective and safe long-term blood pressure control through various techniques, primarily radiofrequency and ultrasound ablation [3][33]. - The approval of RDN devices by the FDA marks a pivotal moment for the commercialization of this therapy, with multiple products already approved in China, indicating a growing market potential [4][37]. Summary by Sections Section 1: Hypertension and RDN - Hypertension is a leading risk factor for cardiovascular diseases, with a rising prevalence due to aging and lifestyle factors [2][16]. - Current pharmacological treatments face adherence issues and limited efficacy for resistant hypertension, necessitating new therapeutic approaches [26][22]. Section 2: Breakthroughs in RDN Therapy - RDN has evolved from initial surgical techniques to a minimally invasive procedure, with significant clinical trials validating its effectiveness [37][38]. - The report discusses the challenges faced in earlier trials, such as the SYMPLICITY HTN-3 study, and the subsequent improvements in trial design and device technology [42][43]. Section 3: Market Development and Competition - The report outlines the competitive landscape, noting that several RDN products have received regulatory approval, with domestic companies innovating to differentiate their offerings [4][9]. - The potential for market expansion is underscored by the increasing number of approved RDN devices and the anticipated growth in patient numbers requiring treatment [4][9]. Section 4: Related Investment Targets - Key investment targets include companies like 百心安, which is noted as a leading domestic RDN manufacturer, and 微电生理, which offers advanced visualization solutions for RDN procedures [9].